Uncharacterized protein ORF106 Antibody

What are uncharacterized proteins and why is ORF106 significant in research?

Uncharacterized proteins represent approximately 10% of all human proteins that have poorly annotated or completely unknown functions . These proteins, which include chromosome-specific open-reading frame genes (CxORFx) from the 'Tdark' category, present significant research opportunities despite their challenging nature . ORF106 belongs to this category of proteins with undefined functions but potential significance in cellular processes.

The study of such proteins is crucial because:

• They represent gaps in our understanding of the proteome

• Their characterization can reveal novel cellular functions

• They may have undiscovered roles in disease mechanisms

• Their identification contributes to the completion of the human proteome project

According to UniProt data from early 2023, the human proteome contains 20,422 canonical and 21,998 non-canonical protein isoforms, with hundreds to thousands remaining uncharacterized .

What techniques are available for detecting uncharacterized proteins like ORF106?

Several complementary techniques can be employed to detect uncharacterized proteins:

For optimal results, experimental protocols should include proper controls such as knockout cell lines to verify antibody specificity . When detecting endogenously expressed uncharacterized proteins, sensitivity is particularly important as expression levels may be low (less than 10 ng of protein per 10 μg of cellular lysate) .

How should researchers validate antibodies against uncharacterized proteins?

• CRISPR/Cas9 knockout validation:

  • Generate knockout cell lines for the target protein

  • Compare antibody signal between wild-type and knockout cells

  • Validate in multiple cell lines with confirmed protein expression

• Multi-technique validation:

  • Test antibody performance in various applications (Western blot, IF, IP)

  • Verify consistent protein detection across techniques

  • Compare results with different antibody clones if available

• Specificity testing:

  • Examine cross-reactivity with similar proteins

  • Test in systems with established negative controls

  • Perform peptide competition assays to confirm epitope specificity

This rigorous approach is critical as studies have shown that many commercially available antibodies fail proper validation tests. For example, a study examining C9ORF72 antibodies found that only 1 out of 16 commercial antibodies accurately detected the protein in immunofluorescence experiments .

How can researchers predict the function of uncharacterized proteins like ORF106?

Function prediction for uncharacterized proteins involves multiple complementary approaches:

A structure-based function prediction approach has proven effective, as demonstrated with the Tm1631 protein from Thermotoga maritima. By comparing its predicted binding site to a library of candidate structures, researchers identified similarities with nucleotide binding sites, specifically a DNA-binding site of endonuclease IV . This prediction was validated through molecular dynamics simulations, showing that structure-based approaches can successfully predict functions even when sequence homology fails.

For uncharacterized proteins like ORF106, researchers should implement multiple prediction methods in parallel to increase confidence in the predicted function .

What strategies help determine the subinteractome of uncharacterized proteins?

The subinteractome analysis of uncharacterized proteins provides crucial insights into potential functions through association with known interaction partners. A comprehensive strategy includes:

• Physical interaction mapping:

  • Affinity purification coupled with mass spectrometry (AP-MS)

  • Yeast two-hybrid screening

  • Proximity-based labeling techniques (BioID, APEX)

  • Integration of data from multiple sources for confidence

• Computational network analysis:

  • Integration of physical protein-protein interactions (PPIs) from multiple databases

  • Network topology analysis to identify functional modules

  • Pathway enrichment analysis of interacting partners

Researchers have successfully applied this approach to uncharacterized CxORFx proteins, revealing their potential involvement in cancer-driven cellular processes. A study examining 219 differentially expressed CxORFx genes in cancers utilized ten different data sources on physical protein-protein interactions, identifying 42 potentially cancer-associated ORF proteins and 30 cancer-dependent binary protein-protein interactions .

How does protein expression data inform the study of uncharacterized proteins?

Expression analysis provides critical context for understanding uncharacterized proteins:

• Tissue-specific expression profiling:

  • Identifies tissues with highest expression levels

  • Guides selection of appropriate cell models

  • Reveals potential physiological contexts

• Differential expression analysis:

  • Compares expression between normal and disease states

  • Identifies conditions where the protein may be functionally relevant

  • Provides prognostic indicators in disease contexts

For example, analysis of CxORFx genes revealed significant associations between their expression and patient survival in various cancers. The table below shows examples of such correlations:

Note: UCEC refers to uterine corpus endometrioid carcinoma .

This approach identified expression patterns of uncharacterized proteins with significant prognostic value, demonstrating how expression data can guide functional characterization efforts.

How can structural biology approaches be applied to characterize ORF106 and develop specific antibodies?

Structural biology offers powerful tools for uncharacterized protein characterization:

• Epitope mapping and structural determination:

  • X-ray crystallography of protein-antibody complexes

  • Cryo-electron microscopy for larger complexes

  • Hydrogen-deuterium exchange mass spectrometry for epitope identification

• Structure-guided antibody development:

  • Identification of exposed, unique regions for antibody targeting

  • Design of antibodies against conserved structural features

  • Optimization of binding interfaces based on structural data

For example, researchers determined the crystal structure of Protein M (a mycoplasma protein) bound to antibodies at 1.2 Å resolution, revealing its mechanism of binding to conserved regions of antibody light chains . This structural information explained how a single bacterial protein could interact with diverse antibodies by targeting structurally conserved regions.

Similar approaches could be applied to ORF106, where structural characterization would:

• Reveal potential functional domains

• Identify optimal epitopes for antibody development

• Guide prediction of protein-protein interactions

• Inform structure-based functional annotation

What are the challenges in developing highly specific antibodies against uncharacterized proteins?

Developing specific antibodies against uncharacterized proteins presents several unique challenges:

• Limited knowledge of protein structure and domains:

  • Difficulty in selecting optimal antigenic regions

  • Unknown post-translational modifications

  • Possible conformational epitopes requiring native protein folding

• Cross-reactivity with related proteins:

  • Unrecognized homology with characterized proteins

  • Conserved domains shared across protein families

  • Challenges in discrimination between closely related isoforms

• Expression and purification obstacles:

  • Difficulty producing recombinant protein for immunization

  • Potential toxicity or instability of the protein

  • Unknown subcellular localization affecting accessibility

These challenges demand rigorous validation strategies. For example, in the development of monoclonal antibodies against the LINE-1 ORF2 protein, researchers found that their antibody specifically recognized human but not mouse ORF2 protein despite strong sequence conservation between the endonuclease domains . This highlights the importance of testing antibodies against closely related proteins to ensure specificity.

How can machine learning approaches improve antibody design for uncharacterized proteins?

Machine learning offers powerful approaches to antibody design for challenging targets:

• Prediction of antibody-antigen interactions:

  • Training models on existing antibody-antigen complex structures

  • Predicting binding modes for novel targets

  • Optimizing antibody sequences for improved affinity and specificity

• Active learning strategies:

  • Starting with small labeled datasets

  • Iteratively expanding labeled data based on model uncertainty

  • Reducing experimental costs while maximizing information gain

A recent study developed fourteen novel active learning strategies for antibody-antigen binding prediction, finding that the best algorithms reduced the number of required antigen variants by up to 35% and accelerated the learning process by 28 steps compared to random baselines . These approaches are particularly valuable for uncharacterized proteins where experimental data is limited.

• Biophysics-informed modeling:

  • Incorporating biophysical constraints into machine learning models

  • Disentangling multiple binding modes

  • Designing antibodies with customized specificity profiles

Researchers demonstrated that biophysics-informed models trained on experimentally selected antibodies can predict outcomes for new ligand combinations and generate novel antibody variants with specific binding properties . Such approaches could be applied to develop antibodies against uncharacterized proteins like ORF106 with desired specificity profiles.

What emerging technologies are advancing the characterization of uncharacterized proteins?

Several cutting-edge technologies are transforming the field:

• High-throughput proteomics approaches:

  • Unbiased protein-protein interaction mapping at proteome scale

  • Protein correlation profiling across subcellular fractions

  • Thermal proteome profiling for ligand discovery

• Functional genomics screens:

  • CRISPR-based genetic screens for phenotypic effects

  • Synthetic lethal/synthetic rescue approaches

  • Perturb-seq combining genetic perturbations with single-cell RNA-seq

• Spatial proteomics technologies:

  • Subcellular localization mapping through fractionation

  • In situ proximity labeling methods

  • Multiplexed immunofluorescence imaging

• Systems biology integration:

  • Multi-omics data integration frameworks

  • Network-based function prediction algorithms

  • Causal inference approaches from perturbation data

A comprehensive systems biology approach for uncharacterized proteins, as demonstrated with CxORFx proteins, combines multiple web servers and databases (GEPIA2, KMplotter, ROC-plotter, TIMER, cBioPortal, DepMap, EnrichR, PepPSy, cProSite, WebGestalt, CancerGeneNet, PathwAX II, and FunCoup) to analyze expression patterns, prognostic significance, and subinteractome composition . This integrative approach represents the future of uncharacterized protein research.